. 2021 Dec 31;9:61. doi: 10.1186/s40635-021-00424-5

Table 2.

Antiviral medications approved and recommended for treatment and chemoprophylaxis of influenza

Antiviral agent (trade name)	Activity against virus	Use	Safety and efficacy	References
Oseltamivir (Tamiflu®)	Influenza A and B	Treatment	Accelerates time to clinical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to hospital	[139], [140], [141], [142]
Oseltamivir (Tamiflu®)	Influenza A and B	Chemoprophylaxis	Modest evidence regarding whether treatment changes the risk of hospitalization or death in high risk populations	[141], [142]
Zanamivir (Relenza®)	Influenza A and B	Treatment	Decreases the risk of becoming symptomatic	[141], [143], [144], [145]
Zanamivir (Relenza®)	Influenza A and B	Chemoprophylaxis	Decreases the risk of becoming symptomatic	[141], [143], [144], [145]
Peramivir (Rapivab®)	Influenza A and B	Treatment	Reduces the time to alleviation of influenza symptoms	[146], [147]
Peramivir (Rapivab®)	Influenza A and B	Chemoprophylaxis	Reduces the time to alleviation of influenza symptoms	[146], [147]
Baloxavir (Xofluza®)	Influenza A and B	Treatment	Effective in alleviating influenza symptoms and reducing the viral load 1 day after initiation	[148], [149], [150], [151], [57], [152]
Baloxavir (Xofluza®)	Influenza A and B	Chemoprophylaxis		[148], [149], [150], [151], [57], [152]
Laninamivir (Inavir®)	Influenza A and B	Treatment	Inhibited the NA activities, reduces duration of symptoms	[153], [154], [155], [56], [156], [55]
Laninamivir (Inavir®)	Influenza A and B	Chemoprophylaxis	Inhibited the NA activities, reduces duration of symptoms	[153], [154], [155], [56], [156], [55]